Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Rectal Neoplasms 3Biliary Tract Neoplasms 3Uterine Cervical Neoplasms 2Nasopharyngeal Carcinoma 2Gastrointestinal Stromal Tumors 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Thymoma 1Stomach Neoplasms 1Squamous Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1Sarcoma 1Rare Tumour 1Prostatic Neoplasms 1Piebaldism 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Multiple Primary 1Neoplasm Metastasis 1NSCLC 1Meningeal Carcinomatosis 1Lung Neoplasms 1Locally Advanced Rectal Carcinoma 1HER2-positive Breast Cancer 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Cholangiocarcinoma 1

Interventions

Radiation Dose Hypofractionation 2Immune Checkpoint Inhibitors 2Granulocyte-Macrophage Colony-Stimulating Factor 2envafolimab 1N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Refractory Solid Tumors × envafolimab × Clear all
NCT07327411 2026-01-08

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow University

Phase 2 Not yet recruiting
40 enrolled
Other solid neoplasm

Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡